\
&
Contact us
\
&
Contact us
Published on | 2 days ago
Programmes Digital Europe SemiconductorsThe Chips for Europe Initiative (the “Initiative”) is established by Pillar I of the European Chips Act for the
duration of the Multiannual Financial Framework 2021-2027. It aims to strengthen the EU's semiconductor
ecosystem, to boost competitiveness and achieve technological sovereignty.The implementation of the Initiative is designed in a way to pool resources from the Union, the Member States as well as the private sector. The total Union funding amounts to 3,3 billion EUR, which includes funding from Horizon Europe and from the Digital Europe Programme (DEP).
Knowledge of underlying EU policies and legislations is a key element in Digital Europe proposals as they play an important role in the “relevance” evaluation criterion. This Policy Briefing is one of several briefings prepared by DEP4ALL, the NCP Network for the Digital Europe programme, to support applicants with summaries of relevant EU initiatives.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
